Cargando…

Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep

Plasma pharmacokinetic profiles and the anti-inflammatory efficacy of meloxicam were determined when administered subcutaneously (SC) or intramuscularly (IM) to sheep. Merino ewes were initially injected with 0.1 mL of oil of turpentine into a forelimb to induce inflammation, followed by either 1.0...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodland, Alyssa N., Van der Saag, Dominique, Kimble, Benjamin, White, Peter J., Govendir, Merran, Lomax, Sabrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481916/
https://www.ncbi.nlm.nih.gov/pubmed/31017959
http://dx.doi.org/10.1371/journal.pone.0215842
_version_ 1783413807979167744
author Woodland, Alyssa N.
Van der Saag, Dominique
Kimble, Benjamin
White, Peter J.
Govendir, Merran
Lomax, Sabrina
author_facet Woodland, Alyssa N.
Van der Saag, Dominique
Kimble, Benjamin
White, Peter J.
Govendir, Merran
Lomax, Sabrina
author_sort Woodland, Alyssa N.
collection PubMed
description Plasma pharmacokinetic profiles and the anti-inflammatory efficacy of meloxicam were determined when administered subcutaneously (SC) or intramuscularly (IM) to sheep. Merino ewes were initially injected with 0.1 mL of oil of turpentine into a forelimb to induce inflammation, followed by either 1.0 mg/kg or 2.0 mg/kg of meloxicam administered either SC or IM (n = 6 per treatment group) or followed by no meloxicam administration (control) (n = 4). Ewes were examined to determine skin temperature, limb circumference, limb sensitivity and signs of lameness at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 48 h following treatment, with blood collected at these time-points to quantify meloxicam plasma concentrations. Skin temperature of ewes dosed with meloxicam at 1.0 mg/kg SC and 2.0 mg/kg IM at 12 h and 1.0 mg/kg SC at 24 were significantly different to the controls (P < 0.05). Limb circumferences of ewes dosed with 1.0 mg/kg IM were significantly different to controls at 10 h and 12 h (P < 0.05). All meloxicam treatment groups resulted in reduced limb sensitivity compared to controls at 6 h, with the 1.0 and 2.0 mg/kg IM treatments significantly different at 12 h (P < 0.05) and 1.0 and 2.0 mg/kg SC groups, significantly different to controls at 48 h (P < 0.05). No significant difference in lameness scores were detected over 48 h. The 1.0 mg/kg IM treatment had a significantly greater plasma meloxicam concentration than the 1.0 mg/kg SC treatment over 0.5 to 4 h (P < 0.001). Both 1.0 mg/kg SC and IM treatments demonstrated elimination half-lives (mean ± SD) of 10.82 ± 2.46 and 12.63 ± 2.37 h, respectively. Meloxicam at all doses provided some anti-inflammatory and analgesic effects from 6 to 48 h; however no route could be distinguished as more efficacious than the others.
format Online
Article
Text
id pubmed-6481916
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64819162019-05-07 Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep Woodland, Alyssa N. Van der Saag, Dominique Kimble, Benjamin White, Peter J. Govendir, Merran Lomax, Sabrina PLoS One Research Article Plasma pharmacokinetic profiles and the anti-inflammatory efficacy of meloxicam were determined when administered subcutaneously (SC) or intramuscularly (IM) to sheep. Merino ewes were initially injected with 0.1 mL of oil of turpentine into a forelimb to induce inflammation, followed by either 1.0 mg/kg or 2.0 mg/kg of meloxicam administered either SC or IM (n = 6 per treatment group) or followed by no meloxicam administration (control) (n = 4). Ewes were examined to determine skin temperature, limb circumference, limb sensitivity and signs of lameness at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 48 h following treatment, with blood collected at these time-points to quantify meloxicam plasma concentrations. Skin temperature of ewes dosed with meloxicam at 1.0 mg/kg SC and 2.0 mg/kg IM at 12 h and 1.0 mg/kg SC at 24 were significantly different to the controls (P < 0.05). Limb circumferences of ewes dosed with 1.0 mg/kg IM were significantly different to controls at 10 h and 12 h (P < 0.05). All meloxicam treatment groups resulted in reduced limb sensitivity compared to controls at 6 h, with the 1.0 and 2.0 mg/kg IM treatments significantly different at 12 h (P < 0.05) and 1.0 and 2.0 mg/kg SC groups, significantly different to controls at 48 h (P < 0.05). No significant difference in lameness scores were detected over 48 h. The 1.0 mg/kg IM treatment had a significantly greater plasma meloxicam concentration than the 1.0 mg/kg SC treatment over 0.5 to 4 h (P < 0.001). Both 1.0 mg/kg SC and IM treatments demonstrated elimination half-lives (mean ± SD) of 10.82 ± 2.46 and 12.63 ± 2.37 h, respectively. Meloxicam at all doses provided some anti-inflammatory and analgesic effects from 6 to 48 h; however no route could be distinguished as more efficacious than the others. Public Library of Science 2019-04-24 /pmc/articles/PMC6481916/ /pubmed/31017959 http://dx.doi.org/10.1371/journal.pone.0215842 Text en © 2019 Woodland et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Woodland, Alyssa N.
Van der Saag, Dominique
Kimble, Benjamin
White, Peter J.
Govendir, Merran
Lomax, Sabrina
Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
title Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
title_full Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
title_fullStr Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
title_full_unstemmed Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
title_short Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
title_sort plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481916/
https://www.ncbi.nlm.nih.gov/pubmed/31017959
http://dx.doi.org/10.1371/journal.pone.0215842
work_keys_str_mv AT woodlandalyssan plasmapharmacokineticprofileandefficacyofmeloxicamadministeredsubcutaneouslyandintramuscularlytosheep
AT vandersaagdominique plasmapharmacokineticprofileandefficacyofmeloxicamadministeredsubcutaneouslyandintramuscularlytosheep
AT kimblebenjamin plasmapharmacokineticprofileandefficacyofmeloxicamadministeredsubcutaneouslyandintramuscularlytosheep
AT whitepeterj plasmapharmacokineticprofileandefficacyofmeloxicamadministeredsubcutaneouslyandintramuscularlytosheep
AT govendirmerran plasmapharmacokineticprofileandefficacyofmeloxicamadministeredsubcutaneouslyandintramuscularlytosheep
AT lomaxsabrina plasmapharmacokineticprofileandefficacyofmeloxicamadministeredsubcutaneouslyandintramuscularlytosheep